Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients with Neuroendocrine Tumors

BACKGROUND & AIMS: Survival times vary among patients with neuroendocrine tumors (NETs)—even among those with the same site, stage, and grade of primary tumor. This makes it difficult to select treatment for patients with unresectable NETs, because some patients can survive decades without treat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gastroenterology
Egile Nagusiak: Tirosh, Amit, Papadakis, Georgios Z., Millo, Corina, Hammoud, Dima, Sadowski, Samira M., Herscovitch, Peter, Pacak, Karel, Marx, Stephen J., Yang, Lily, Nockel, Pavel, Shell, Jasmine, Green, Patience, Keutgen, Xavier M., Patel, Dhaval, Nilubol, Naris, Kebebew, Electron
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5847442/
https://ncbi.nlm.nih.gov/pubmed/29155309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2017.11.008
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak